UBS O'Connor’s Starling Oncology, Inc. Warrant STLNW Stock Holding History

UBS O'Connor’s Portfolio STLNW Stock Details STLNW Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-372,284	Closed	-$577K	–	1013
2021 Q3	$577K	Hold	372,284	–	–	﹤0.01%	639
2021 Q2	$655K	Hold	372,284	–	–	0.01%	594
2021 Q1	$531K	Buy	+372,284	New	+$690K	0.01%	599

Other funds holding STLNW

LMR Partners London, United Kingdom $45.4B AUM 60.47% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

HCM

Highbridge Capital Management New York $3.09B AUM 31.21% 1-Year Est. Return

DKCM

Davidson Kempner Capital Management New York $7.33B AUM 56.47% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

DCM

Difesa Capital Management New York $38.1M AUM 39.86% 1-Year Est. Return

USPCM

Union Square Park Capital Management New York $176M AUM 51.52% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return

UBS O'Connor's STLNW Position: Q4 2021 in Review

UBS O'Connor sold out of Starling Oncology, Inc. Warrant (STLNW) in Q4 2021, closing a stake of 372,284 shares — an estimated $577K sold.

UBS O'Connor first reported a position in STLNW in Q1 2021 and held it in 3 quarters. The position peaked at $655K in Q2 2021. 20 funds tracked by Wall St. Rank hold STLNW as of Q4 2021.

UBS O'Connor reported no remaining Starling Oncology, Inc. Warrant position as of Q4 2021 after selling out during the quarter.
UBS O'Connor sold 372,284 Starling Oncology, Inc. Warrant shares in Q4 2021, an estimated $577K.
UBS O'Connor first reported a position in Starling Oncology, Inc. Warrant in Q1 2021 and held it in 3 quarters.
UBS O'Connor's Starling Oncology, Inc. Warrant position peaked at $655K in Q2 2021.
20 funds tracked by Wall St. Rank held Starling Oncology, Inc. Warrant as of Q4 2021.

Based on UBS O'Connor's 13F filing for Q4 2021, filed 14 Feb 2022.